Financials data is unavailable for this security.
View more
Year on year Talis Biomedical Corp had revenues fall -55.65% from 4.81m to 2.13m, though the company grew net income from a loss of 113.01m to a smaller loss of 62.01m.
Gross margin | 95.10% |
---|---|
Net profit margin | -12,506.37% |
Operating margin | -13,510.29% |
Return on assets | -52.13% |
---|---|
Return on equity | -70.48% |
Return on investment | -57.23% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Talis Biomedical Corp fell by 53.69m. Cash Flow from Financing totalled 33.00k or 1.55% of revenues. In addition the company used 53.24m for operations while cash used for investing totalled 486.00k.
Cash flow per share | -27.59 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 26.69 |
---|---|
Tangible book value per share | 26.69 |
More ▼
Balance sheet in USDView more
Current ratio | 7.76 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 46.40%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 41.53 |